ESTRO 2024 - Abstract Book

S5566

RTT - Patient care, preparation, immobilisation and IGRT verification protocols

ESTRO 2024

Conclusion:

This study shows that renal SABR treatment delivery is challenging due to the poor visualisation of the OARs, particularly the small bowel in on-treatment CBCTs. This is of particular significance since the motion of small bowel is well reported, but unpredictable in clinical practice. This suggests further investigation in CBCT optimisation is required, either with the use of contrast enhancement or improvement in image acquiition parameters.

Keywords: Renal, SABR, bowel

References:

1. UK SABR Consortium (2019) Stereotactic Ablative Body Radiation Therapy (SABR): A Resource. Available at: https://www.sabr.org.uk/wp-content/uploads/2019/04/SABRconsortium-guidelines-2019-v6.1.0.pdf (Accessed 2 January 2023). 2. Franzese, C., Marini, B., Baldaccini, D., Badalamenti, M., Navarria, P., Bellu, L., Franceschini, D., Comito, T., Clerici, E., Teriaca, M.A., Massaro, M., Di Cristina, L., Lo Faro, L., Tomatis, S. and Scorsetti, M. (2022) 'The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma', Journal of Cancer Research and Clinical Oncology, pp.1-7. Available at: https://doi.org/10.1007/s00432-022-04352-z 3. Hannan, R., Christensen, M., Hammers, H., Christie, A., Paulman, B., Lin, D., Garant, A., Arafat, W., Courtney, K., Bowman, I. and Cole, S. (2022) 'Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer', European Urology Oncology, 5(2), pp.216-224. Available at: https://doi.org/10.1016/j.euo.2021.12.001 4. Le Guevelou, J., Sargos, P., Siva, S., Ploussard, G., Ost, P., Gillessen, S. and Zilli, T. (2022) 'The emerging role of extracranial stereotactic ablative radiotherapy for metastatic renal cell carcinoma: a systematic review', European Urology Focus. Available at: https://doi.org/10.1016/j.euf.2022.08.016 5. Siva, S., Ali, M., Correa, R.J., Muacevic, A., Ponsky, L., Ellis, R.J., Lo, S.S., Onishi, H., Swaminath, A., McLaughlin, M.,Morgan, S.C., Cury, F.L., Teh, B.S., Mahadevan, A., Kaplan, I.D., Chu, W., Grubb, W., Hannan, R., Staehler, M., Warner, A. and Louie, A.V. (2022) '5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)', The Lancet Oncology, 23(12), pp.1508-1516. Available at: https://doi.org/10.1016/S1470-2045(22)00656-8 6. Diez, P., Hanna, G.G., Aitken, K.L., van As, N., Carver, A., Colaco, R.J., Conibear, J., Dunne, E.M., Eaton, D.J., Franks, K.N., Good, J.S., Harrow, S., Hatfield, P., Hawkins, M.A., Jain, S., McDonald, F., Patel, R., Rackley, T., Sanghera, P., Tree, A. and Murray, L. (2022) 'UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy', Clinical Oncology, 34(5), pp.288-300. Available at: https://doi.org/10.1016/j.clon.2022.02.010 7. Royal College of Radiologists (2021) On target 2: updated guidance for image-guided radiotherapy. London. Available at: https://www.rcr.ac.uk/sites/default/files/radiotherapy-board-on-target-2-updated-guidance-image guided-radiotherapy.pdf (Accessed 2 January 2023)